tigarb Antibody

What is TIGAR/tigarb and why is it relevant to neurodegeneration research?

TIGAR (TP53-Induced Glycolysis and Apoptosis Regulator) is a protein involved in glucose metabolism and cellular stress response. Tigarb is the zebrafish orthologue of human TIGAR. The significance of TIGAR in neurodegeneration research stems from its up-regulation in pink1-/- zebrafish models of Parkinson's disease (PD), with subsequent genetic inactivation of tigarb rescuing dopaminergic neurons and mitochondrial function . Moreover, TIGAR has been detected in Lewy bodies and Lewy neurites in the substantia nigra of patients with sporadic PD and Dementia with Lewy bodies (DLB), suggesting a potential role in the pathogenesis of these conditions .

Which antibodies are most suitable for detecting TIGAR in Lewy bodies?

For detection of TIGAR in Lewy bodies, antibodies targeting the C-terminus of TIGAR are most effective. Studies have demonstrated that three different antibodies directed against the C-terminus (ab129333, LS-C286858, and PA5-29152) specifically labeled brainstem Lewy bodies . In contrast, antibodies that recognize the central region of TIGAR (ab62533 and ab10545) showed diffuse, non-specific neuronal staining and cross-reactivity with neuromelanin, but did not label Lewy bodies . The C-terminus antibodies labeled a region deep to the 'halo' of the Lewy body but not the most central region, suggesting TIGAR incorporation may be a late event in Lewy body formation .

How can I differentiate between tigarb and human TIGAR when using antibodies?

When designing experiments to differentiate between tigarb (zebrafish) and human TIGAR, researchers should:

• Select antibodies with validated species specificity

• Perform sequence alignment analysis between human TIGAR and zebrafish tigarb to identify conserved and divergent epitopes

• Include appropriate controls such as tissues from TIGAR/tigarb knockout models

• Use Western blot analysis to confirm antibody specificity by molecular weight differences

• Consider using species-specific primers for RT-qPCR validation in conjunction with antibody studies

What immunohistochemistry protocols are recommended for TIGAR detection in brain tissue?

For optimal TIGAR detection in brain tissue, the following protocol has proven effective:

• Use formalin-fixed, paraffin-embedded tissue sections

• For automated staining, employ systems such as the IntelliPATH FLX Detection Kit and autostainer system (Menarini Diagnostics)

• For double-labeling studies with alpha-synuclein, use either:

  • Anti-alpha-synuclein antibody with Alexa Fluor 488/555 and TIGAR labeled with DAB, or

  • Both alpha-synuclein and TIGAR in fluorescence

• Apply Sudan Black treatment to mask autofluorescent material

• For detailed comparative studies, stain adjacent sections for TIGAR and alpha-synuclein, then digitize and align the slide images to assess the same structures across both sections

How should RNA isolation be performed when studying tigarb expression in zebrafish models?

For effective RNA isolation from zebrafish models studying tigarb expression:

• Pool 5 larvae according to genotype at designated time points

• Suspend larvae in 200 μl of Trizol and freeze at -80°C for at least 24 hours

• After defrosting, add sterile zirconium oxide beads and disrupt tissue using a Bullet Blender (5 minutes at speed level 8)

• Briefly centrifuge and perform phenol-chloroform extraction on the supernatant

• Remove DNA contaminants via DNase treatment

• Concentrate RNA using an RNA Clean and Concentration kit

• Assess RNA quality and quantity using spectrophotometry

This methodology ensures high-quality RNA for subsequent RT-qPCR analysis of tigarb expression.

What is the recommended approach for validating TIGAR antibody specificity?

To validate TIGAR antibody specificity, researchers should:

• Test multiple antibodies targeting different regions of the protein (e.g., C-terminus vs. central region)

• Perform Western blot analysis on tissues from both control and disease models

• Include negative controls such as TIGAR knockout tissues

• Conduct peptide competition assays to confirm epitope specificity

• Verify findings through double-labeling with established markers (e.g., alpha-synuclein for Lewy body studies)

• Compare staining patterns on adjacent tissue sections using different antibodies

• Validate findings across independent case series of sufficient size to avoid spurious results

How does TIGAR expression in Parkinson's disease differ from other neurodegenerative conditions?

TIGAR demonstrates distinctive expression patterns across different neurodegenerative diseases:

• In Parkinson's disease (PD) and Dementia with Lewy bodies (DLB):

  • TIGAR protein is present in substantia nigra Lewy bodies and Lewy neurites

  • TIGAR colocalizes with alpha-synuclein in these inclusions

  • C-terminus TIGAR antibodies specifically label brainstem Lewy bodies

• In other neurodegenerative conditions:

  • TIGAR is absent in cortical Lewy bodies of DLB

  • TIGAR is not detected in TDP-43-positive inclusions in Motor Neurone Disease (MND)

  • TIGAR is absent in glial cytoplasmic inclusions in Multiple System Atrophy (MSA)

This disease specificity suggests that TIGAR may play a particular role in the pathogenesis of brainstem-predominant Lewy body disorders.

What is the relationship between TIGAR and alpha-synuclein in Lewy bodies?

The relationship between TIGAR and alpha-synuclein in Lewy bodies reveals important insights into disease mechanisms:

• Colocalization studies demonstrate that TIGAR and alpha-synuclein are present together in Lewy bodies in the substantia nigra of PD and DLB patients

• TIGAR appears to be incorporated into a specific region of the Lewy body—deep to the peripheral "halo" but not in the central core—suggesting TIGAR incorporation may be a late event in Lewy body formation

• The mechanism of TIGAR incorporation into Lewy bodies remains unclear but may represent:

  • A cellular self-defense mechanism to sequester potentially cytotoxic proteins

  • A component of the protein aggregation process in synucleinopathies

  • A response to oxidative stress and metabolic dysfunction in affected neurons

How can TIGAR rescue experiments be designed in zebrafish models?

When designing TIGAR rescue experiments in zebrafish models:

• Generate full-length wild-type and mutated coding sequences (CDS) of mia40a and mia40b from appropriate cDNA using specific primers

• Clone amplicons into expression vectors (e.g., pCS2+) and confirm correct inserts by sequencing

• Linearize plasmids and transcribe mRNA using an appropriate synthesis kit (e.g., mMESSAGE mMACHINE SP6)

• Purify mRNA and assess quality via spectrophotometry and gel electrophoresis

• Determine the optimal dosage by injecting different amounts (50-500ng) at the 1-cell stage into embryos from heterozygous crosses

• Select the highest dose that doesn't trigger severe phenotypes

• Analyze results using confocal microscopy at appropriate developmental stages (e.g., 3 dpf)

What are the implications of different TIGAR antibody epitope recognition for pathology studies?

The differential recognition of TIGAR epitopes by various antibodies has significant implications for pathology studies:

• C-terminus vs. Central Region Recognition:

  • C-terminus-specific antibodies (ab129333, LS-C286858, PA5-29152) successfully label Lewy bodies

  • Central region-specific antibodies (ab62533, ab10545) fail to detect TIGAR in Lewy bodies

• Potential Explanations:

  • TIGAR may undergo cleavage prior to incorporation into Lewy bodies

  • Post-translational modifications might render the central portion unavailable for antibody binding

  • Protein conformational changes within Lewy bodies might expose C-terminal epitopes while masking central regions

• Research Implications:

  • Studies investigating TIGAR in neurodegenerative disorders must carefully select antibodies based on target epitopes

  • Negative findings with central region antibodies do not necessarily indicate TIGAR absence

  • Comprehensive studies should employ multiple antibodies targeting different regions

How can researchers quantitatively assess TIGAR-positive structures in neuropathological samples?

For quantitative assessment of TIGAR-positive structures in neuropathological samples:

• Digitize immunostained slides using a whole-slide scanner (e.g., Hamamatsu NanoZoomer XR)

• Analyze digitized images using appropriate viewing platforms (e.g., Hamamatsu NDP view)

• Employ blinded assessment by multiple experienced neuropathologists to reduce bias

• Quantify:

  • Proportion of TIGAR-positive neurons relative to total neuronal population

  • Number of TIGAR-positive neurites per field

  • Co-localization percentages with other disease markers

• Statistical Considerations:

  • Use sufficiently large case series (minimum n=6 per group)

  • Compare findings across independent cohorts to validate results

  • Be cautious of initial findings in small cohorts that may represent spurious results

What are the current hypotheses regarding TIGAR's role in the pathogenesis of Parkinson's disease?

Current hypotheses regarding TIGAR's role in Parkinson's disease pathogenesis include:

• Metabolic Regulation Hypothesis:

  • TIGAR normally inhibits glycolysis and promotes the pentose phosphate pathway

  • In PD, TIGAR upregulation may disrupt cellular energy metabolism

  • This disruption potentially contributes to mitochondrial dysfunction observed in PD

• Cellular Defense Mechanism Hypothesis:

  • TIGAR inclusion in Lewy bodies may represent a cellular attempt to sequester potentially harmful proteins

  • This is supported by findings that TIGAR knockdown rescued dopaminergic neurons in zebrafish PD models

• Dual Function Hypothesis:

  • TIGAR may have context-dependent effects, either protective or detrimental

  • In some systems, TIGAR provides protection against oxidative stress

  • In the context of PD, excessive TIGAR activity may become pathological

  • The balance between these functions may determine disease progression

What novel bispecific antibody approaches might be relevant for studying TIGAR in combination with other neurodegeneration markers?

Novel bispecific antibody approaches for studying TIGAR with other neurodegeneration markers could include:

• Native-format bispecific antibodies:

  • Utilizing the recently developed native human immunoglobulin format bispecific antibodies

  • This format exploits differences in affinities of immunoglobulin isotypes for Protein A, allowing efficient large-scale purification

  • Such antibodies could simultaneously target TIGAR and alpha-synuclein, providing direct visualization of their interaction in Lewy bodies

• Potential applications:

  • Single-molecule imaging of TIGAR/alpha-synuclein interactions in real-time

  • Flow cytometry-based quantification of neurons containing both markers

  • Therapeutic targeting of pathological protein interactions

• Methodological advantages:

  • Superior stability and reduced immunogenicity compared to scFv-based bispecifics

  • Longer serum half-life (approximately 14 days based on similar formats)

  • Potential for deeper tissue penetration in brain tissue analysis

How can RNA rescue experiments be optimized when studying tigarb function in disease models?

To optimize RNA rescue experiments when studying tigarb function:

• Design construct specificity:

  • Create both wild-type and mutated versions of the gene to determine specificity

  • Ensure complete coverage of the coding sequence

  • Verify constructs through sequencing before transcription

• Dosage optimization:

  • Test multiple concentrations (50-500ng range)

  • Identify highest non-toxic dose that doesn't trigger developmental abnormalities

  • Consider temporal delivery strategies for stage-specific rescue

• Phenotypic assessment:

  • Implement quantitative metrics for rescue evaluation

  • Use transgenic reporter lines to visualize affected tissues

  • Employ confocal microscopy for detailed cellular analysis

• Controls and validation:

  • Include injection controls with non-relevant mRNA

  • Validate rescue through molecular markers beyond morphological assessment

  • Perform complementary genetic approaches (CRISPR-based) to confirm findings

What are the implications of TIGAR's absence in cortical Lewy bodies despite presence in brainstem Lewy bodies?

The differential presence of TIGAR in brainstem versus cortical Lewy bodies has several important research implications:

• Regional vulnerability hypotheses:

  • The substantia nigra may have unique metabolic requirements making TIGAR incorporation more likely

  • Cortical neurons might process or respond to TIGAR differently than brainstem neurons

  • This regional selectivity might explain why certain neuron populations are more vulnerable in synucleinopathies

• Lewy body formation mechanisms:

  • Suggests fundamental differences in the composition and possibly formation of Lewy bodies across brain regions

  • Indicates that Lewy bodies are not homogeneous structures but vary depending on neuroanatomical location

  • Challenges the concept of a universal mechanism for Lewy body formation

• Methodological considerations for researchers:

  • Regional differences necessitate sampling from multiple brain areas when studying protein incorporation into Lewy bodies

  • Negative findings in cortical regions should not be extrapolated to brainstem regions

  • Comprehensive studies must assess both brainstem and cortical pathology to fully understand protein dynamics in synucleinopathies